Akademik Veri Yönetim Sistemi
ESMO 2025, Berlin, Almanya, 17 - 21 Ekim 2025, ss.1462, (Özet Bildiri)
Background: Trabectedin is a standard treatment for advanced soft tissue sarcomas (STS) after anthracycline failure. However, predictive and prognostic markers remain limited. This study aims to evaluate the prognostic significance of inflammatory indices and the modified Glasgow Prognostic Score (mGPS) in STS patients treated with trabectedin. Methods: We retrospectively analyzed 60 patients with advanced STS who received trabectedin between 2015 and 2024. Baseline inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), pan-immune-inflammation value (PIV), inflammatory burden index (IBI), and prognostic nutritional index (PNI), were evaluated. Cut-off values were set at the median, except for IBI (optimal cut-off: 9.5, AUC: 0.75; 95% CI: 0.58—0.92,with sensitivity 90% and specificity 62%). Cox regression models assessed their association with overall survival (OS). Results: A total of 37 patients (61.7%) were female, with a median age of 54.5 years (range: 35—77). Leiomyosarcoma was the predominant histological subtype, observed in 55% of cases. Trabectedin was administered at a median of the third-line setting (range: 1st to 5th line). The objective response rate (ORR) was 20%, while the disease control rate (DCR) was 50%. The median follow-up duration was 10.2 months (range: 1—50.7). Median progression-free survival (PFS) was 4.9 months, and median overall survival (OS) was 11.7 months. Elevated platelet-to-lymphocyte ratio (PLR ≥184.9) and inflammatory burden index (IBI ≥9.5) were associated with poorer OS in univariate analysis (HR: 2.0, p=0.01; HR: 1.9, p=0.04, respectively). Patients with a modified Glasgow Prognostic Score (mGPS) of 0 had significantly longer OS compared to those with mGPS 1 or 2 (median OS: 20.5 vs. 10.1 and 10.9 months, respectively; p=0.006), and mGPS 0 remained an independent prognostic factor in multivariate analysis (HR: 3.2, p=0.009). Conclusions: Inflammatory markers, particularly PLR, IBI, and mGPS, may serve as prognostic indicators in STS patients receiving trabectedin. mGPS 0 identifies a subgroup with significantly better survival and may guide patient stratification in future studies